Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
Rapid Review
| Commenced | Completed | Outcome |
| 26/01/2016 | 09/02/2016 | Full Pharmacoeconomic Evaluation Recommended |
Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation